Three products of New Horizon Health (HKG:6606) have recently been listed with the Hong Kong government's Department of Health under the Medical Device Administrative Control System (MDACS), a Tuesday bourse filing said.
The products include ColoClear, a screening test for colorectal cancer; Pupu Tube, a screening product to detect hemoglobin biomarkers associated with colorectal cancer; and UU Tube, a screening product for H. pylori.
Medical devices can be listed with the Department of Health using MDACS if they conform to the accepted standards of safety and performance.
Trading in the company's shares, which was suspended March 28, remains suspended.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。